Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Carcinoma of unknown primary remains a management problem without an established approach demonstrated to prolong survival. In a phase II study, the combination of carboplatin, gemcitabine, and capecitabine was shown to be fairly well tolerated and, for certain subsets, effective in producing transient tumor regression.

Combination Chemotherapy for Unknown Primary